5 :: KDA, Korean Diabetes Association ::
string(8) "resource"
Subject    :    [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Writer KDA
Date 2017-07-06 11:02:30 Hit 8,900
Diabetes Metab J. 2017 Apr;41(2):135-145. English.
Published online Jan 11, 2017.  https://doi.org/10.4093/dmj.2017.41.2.135 
Copyright © 2017 Korean Diabetes Association
   
Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Kyung-Wan Min,1 Bon Jeong Ku,2 Ji-Hyun Lee,3 Min-Seon Kim,4 Kyu-Jeung Ahn,5 Moon-Kyu Lee,6 Satoshi Kokubo,7 Satoshi Yoshida,7 Hyun-Ji Cho,8 and Bong-Soo Cha9
1Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.
2Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
3Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.
4Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
5Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical Center, Seoul, Korea.
6Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
7Astellas Pharma Inc., Tokyo, Japan.
8Astellas Korea Inc., Seoul, Korea.
9Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Bong-Soo Cha. Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Email: bscha@yuhs.ac 
 
Received August 01, 2016; Accepted October 25, 2016.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Background

This is a subgroup analysis of Korean patients from a phase 3 clinical trial investigating the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin.

Methods

This multicenter, placebo-controlled, double-blind, parallel-group study was carried out between November 2011 and January 2013. Patients entered a 2-week placebo pretreatment period, followed by a 24-week treatment period with either ipragliflozin (50 mg/day) or placebo, while continuing metformin. Efficacy outcomes (glycosylated hemoglobin [HbA1c], fasting plasma glucose [FPG], and body weight) and safety outcomes (treatment-emergent adverse events [TEAEs]) were measured and compared between the two treatment groups for patients enrolled in all 18 study sites in Korea.

Results

Eighty-two Korean patients received ipragliflozin (n=43) or placebo (n=39) during the study period. Mean changes in HbA1c levels from baseline to the end of treatment were –0.97% in the ipragliflozin group and –0.31% in the placebo group, with an adjusted between-group difference of –0.60% (P P

Conclusion

Ipragliflozin treatment in addition to metformin led to significant improvement in glycemic outcomes and reduction in body weight in Korean patients with type 2 diabetes mellitus, compared with metformin treatment alone; the safety profile was comparable in both groups.

   
Keywords:
Asia; Diabetes mellitus, type 2; Ipragliflozin; Korea; Metformin; Randomized controlled trial; Sodium-glucose cotransporter 2 inhibitor

Articles - Reviews in DMJ
No. Subject Date Hit ↑
Notice : [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iron-Deficiency Anemia [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iro... 2019-10-10 773
Notice : [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrom... 2019-10-10 761
Notice : [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabo... 2019-10-10 753
Notice : [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Aci... 2019-10-10 760
Notice : [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in ... 2019-10-10 751
Notice : [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal o... 2019-10-10 723
Notice : [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes Mellitus in A Chinese Population: A Nested Case-Control Study [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes ... 2019-10-10 710
Notice : [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuria Independently of Obesity, Insulin Resistance, and Metabolic Syndrome (Korea National Health and Nutrition Examination Surveys 2008 to 2011) [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuri... 2019-10-10 722
Notice : [2019 Aug;43(4)] Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies [2019 Aug;43(4)] Association between Serum Selenium Level and the Pr... 2019-10-10 714
Notice : [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Gl... 2019-10-10 701
Notice : [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with... 2019-10-10 718
Notice : [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovasc... 2019-10-10 708
Notice : [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabet... 2019-10-10 728
Notice : [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes ... 2019-10-10 713
Notice : [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Ob... 2019-06-28 2,055
Notice : [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood... 2019-06-28 2,197
Notice : [2019 June;43(3)]  Oral Glucose Tolerance Testing Allows Better Prediction of Diabetes in Women with a History of Gestational Diabetes Mellitus [2019 June;43(3)] Oral Glucose Tolerance Testing Allows Better Pred... 2019-06-28 2,045
Notice : [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A ... 2019-06-28 2,051
Notice : [2019 June;43(3)]  Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis [2019 June;43(3)] Effectiveness of Exercise Intervention in Reducin... 2019-06-28 2,001
Notice : [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Di... 2019-06-28 2,434
Notice : [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in... 2019-06-28 1,988
Notice : [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: Fro... 2019-06-28 1,979
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 2,237
292 [2017 Jun;41(3)] Satisfaction Survey on Information Technology-Based... 2017-07-06 9,709
291 [2017 Jun;41(3)] The Effect of 12 Weeks Aerobic, Resistance, and Com... 2017-07-06 9,547
290 [2017 Jun;41(3)] Impact of Gender on the Association between Low Ser... 2017-07-06 9,238
289 [2017 Jun;41(3)] Comparison of Antidiabetic Regimens in Patients wit... 2017-07-06 9,014
288 [2017 Jun;41(3)] Physician-Directed Diabetes Education without a Med... 2017-07-06 8,993
287 [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in... 2017-07-06 8,900
286 [2017 Apr;41(2)] Association between Blood Mercury Level and Viscera... 2017-07-06 8,891
285 [2017 Apr;41(2)] Diabetes Camp as Continuing Education for Diabetes ... 2017-07-06 8,865
284 [2017 Feb;41(1)] Relationship between Regional Body Fat Distribution... 2017-03-23 8,846
283 [2017 Apr;41(2)] Role of NO/VASP Signaling Pathway against Obesity-R... 2017-07-06 8,792

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.